- Home
- DV vs ACAD Comparison
DV vs ACAD Comparison
Compare DV & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- ACAD
- Stock Information
- Founded
- DV 2008
- ACAD 1993
- Country
- DV United States
- ACAD United States
- Employees
- DV N/A
- ACAD N/A
- Industry
- DV Computer Software: Prepackaged Software
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- DV Technology
- ACAD Health Care
- Exchange
- DV Nasdaq
- ACAD Nasdaq
- Market Cap
- DV 2.2B
- ACAD 2.5B
- IPO Year
- DV 2021
- ACAD 2004
- Fundamental
- Price
- DV $13.34
- ACAD $17.44
- Analyst Decision
- DV Buy
- ACAD Buy
- Analyst Count
- DV 18
- ACAD 15
- Target Price
- DV $19.08
- ACAD $24.21
- AVG Volume (30 Days)
- DV 2.3M
- ACAD 1.7M
- Earning Date
- DV 05-08-2025
- ACAD 05-07-2025
- Dividend Yield
- DV N/A
- ACAD N/A
- EPS Growth
- DV N/A
- ACAD N/A
- EPS
- DV 0.29
- ACAD 1.37
- Revenue
- DV $681,128,000.00
- ACAD $996,283,000.00
- Revenue This Year
- DV $13.06
- ACAD $13.07
- Revenue Next Year
- DV $12.77
- ACAD $10.06
- P/E Ratio
- DV $45.55
- ACAD $12.73
- Revenue Growth
- DV 15.30
- ACAD 22.42
- 52 Week Low
- DV $11.52
- ACAD $13.40
- 52 Week High
- DV $23.11
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- DV 48.38
- ACAD 67.70
- Support Level
- DV $13.16
- ACAD $14.45
- Resistance Level
- DV $13.63
- ACAD $15.31
- Average True Range (ATR)
- DV 0.44
- ACAD 0.69
- MACD
- DV 0.19
- ACAD 0.37
- Stochastic Oscillator
- DV 52.15
- ACAD 94.92
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.